Advice
in the absence of a submission from the holder of the marketing authorisation:
corifollitropin alfa (Elonva ®) is not recommended for use within NHSScotland for the treatment of Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice46KB (PDF)
Medicine details
- Medicine name:
- corifollitropin alfa (Elonva)
- SMC ID:
- 633/10
- Indication:
- for the treatment of Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.
- Pharmaceutical company
- MSD
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 July 2010